<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-77582</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Recommendations of antifungal treatment in patients with low grade inmunosuppression</dc:title>
<dc:description xml:lang="en">Because of the relevance that the systemic mycoses hasacquired in non-highly immunocompromised patients, thetreatment difficulties they have due to the increase of thenon-albicans Candida species and the need to have a betterand more rational use of the new antifungal agents (voriconazole,posaconazole, caspofungin, anidulafungin and micafungin),an experts' panel on infectious diseases in representationof the Spanish Society of Chemotherapy, SpanishSociety of Internal Medicine, and Spanish Society of Pneumologyand Thoracic Surgery has met in order to make a few recommendations based on the scientific evidence in aneffort to improve their efficiency (AU)</dc:description>
<dc:creator>Barberán, J</dc:creator>
<dc:creator>Mensa, J</dc:creator>
<dc:creator>Llinares, P</dc:creator>
<dc:creator>Agusti, C</dc:creator>
<dc:creator>Menéndez, R</dc:creator>
<dc:creator>García Rodríguez, J. A</dc:creator>
<dc:creator>Fariñas, C</dc:creator>
<dc:creator>Serrano, R</dc:creator>
<dc:creator>Gobernado, M</dc:creator>
<dc:creator>Azanza, J. R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La relevancia que las micosis sistémicas han adquiridoen los pacientes no profundamente inmunodeprimidos, lasdificultades de tratamiento que presentan por el incrementode la especies de Candida no albicans y la necesidad dehacer un mejor uso y más racional de los nuevos antifúngicos(voriconazol, posaconazol, caspofungina, micafungina yanidulafungina) han reunido a un panel de expertos en enfermedadesinfecciosas en representación de la Sociedad Españolade Quimioterapia (SEQ), Sociedad Española de MedicinaInterna (SEMI) y Sociedad Española de Neumología yCirugía Torácica (SEPAR) para hacer unas recomendacionesbasadas en la evidencia científica buscando mejorar la efectividad (AU)</dc:description>
<dc:source>Rev Esp Quimioter;21(2): 127-142, jun. 2008. tab</dc:source>
<dc:identifier>ibc-77582</dc:identifier>
<dc:title xml:lang="es">Recomendaciones de tratamiento antifúngico en pacientes con bajo gradode inmunodepresión</dc:title>
<dc:subject>^d9373^s22053</dc:subject>
<dc:subject>^d943^s22048</dc:subject>
<dc:subject>^d943^s22000</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d943^s22073</dc:subject>
<dc:subject>^d943^s22020</dc:subject>
<dc:subject>^d13411^s22080</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d7414^s22080</dc:subject>
<dc:subject>^d7414^s22067</dc:subject>
<dc:subject>^d7414^s22032</dc:subject>
<dc:subject>^d9373^s22027</dc:subject>
<dc:subject>^d9373^s22038</dc:subject>
<dc:subject>^d9373^s22012</dc:subject>
<dc:subject>^d9373^s22067</dc:subject>
<dc:type>article</dc:type>
<dc:date>200806</dc:date>
</metadata>
</record>
</ibecs-document>
